GeneArt™ Precision TAL Construction Service, Truncated TAL FokI - FAQs

View additional product information for GeneArt™ Precision TAL Construction Service, Truncated TAL FokI - FAQs (816511DE)

29 product FAQs found

What are TALs or TALENS?

TALs or TALENs are transcription activator-like effector nuclease proteins that are naturally occurring transcriptional activators secreted by Xanthomonas spp. into their plant hosts. GeneArt TALs are derived from Xathomonas TAL effectors, the DNA-binding domain of which consists of a variable number of amino acid repeats. Each repeat contains 33–35 amino acids and recognizes a single DNA base pair. The DNA recognition occurs via 2 hypervariable amino acid residues at positions 12 and 13 within each repeat, called repeat-variable di-residues (RVDs). TAL effector repeats can be assembled in modular fashion, varying the RVDs to create a TAL protein that recognizes a specific target DNA sequence.

I am working with TALs and want to incorporate an effector domain that you do not carry. What should I do?

We do offer a multiple cloning site sequence in the place of the effector domain sequence for our TAL MCS entry vector. This option allows you to insert any protein-coding sequence, and allows your resulting TAL protein to deliver the effector in a sequence-specific manner anywhere in the genome. We also provide gene synthesis services to generate any effector domain for which you don't have a template.

I am trying to design my TAL but do not have a T at the 5´ end of the TAL effector. What should I do?

While our Invitrogen GeneArt Precision TALs required a T at the 5´end and 13-18 bp spacing between the forward and reverse TAL effectors for proper pairing of Fok1 nucleases, the Invitrogen GeneArt PerfectMatch TALs allow for targeting of any sequence across the genome and eliminates the 5´ T constraints. Additionally, the spacing between the two effectors is optimal at 15-16 bp.

The binding domain for TALs can be either 19 or 25 bp in length. Does one work better than the other?

The 19 bp binding domains perform better for the nucleases. The binding sites do not need to be the same size; however, best performance for the nucleases is with the 19 bp binding domains.

I'm hoping to use one set of TALs to knockout two genes. I have identified potential binding sites, but I could not find a spot with 100% homology between the two genes. Will the TAL work if there is a 1 or 2 bp mismatch in the binding domain?

We have observed that as little as 3 bp mismatch affects the binding of the TALs. We recommend that there be an exact match between the design and the binding site. If you would like some help with the design, please email geneartsupport@lifetech.com.

I just received my Invitrogen GeneArt TALs vectors. Can I store them lyophilized?

We recommend that you resuspend the vector in 50 µL of distilled water or 10 mM Tris-HCl (pH 8.0) and incubate for 1 hour at room temperature. Resuspend the vector DNA by gently pipetting up and down 5-10 times. Store the resuspended DNA at -20°C.

I have questions regarding licensing of TALs that is not covered under the Limited-Use Label License (LULL). Whom should I contact?

Please email our team, at outlicensing@lifetech.com.

Do I need to use a specific transfection reagent when working with a TAL effector vector?

No, we would recommend either lipid-mediated transfection or electroporation. Please review relevant references or consult with the supplier of your cell line for the optimal method of transfection.

How can an Invitrogen GeneArt Precision TAL protein fused to a Fok1 endonuclease be used to induce gene silencing or to insert an engineered DNA fragment into an exact location in the genome?

Double-stranded DNA breaks can be created at your specified genomic locus by using a pair of Invitrogen GeneArt Precision TAL proteins that have been fused to the Fok1 endonuclease. Using a pair of Precision TAL proteins for the targeting reduces off-target effects. The breaks induced by the Fok1 nuclease domain are subsequently repaired through either of two endogenous cellular mechanisms: nonhomologous end joining (NHEJ), or homology-directed repair (HDR). NHEJ is prone to errors and often introduces a frameshift mutation when it occurs within the coding sequence of a protein-coding gene, effectively silencing the gene. Homologous DNA “donor sequences” can be used with HDR to introduce a defined new DNA sequence. Consequently, a Precision TAL protein fused to a Fok1 endonuclease can be used to induce gene silencing or to accurately insert an engineered DNA fragment into an exact location in the genome.

When should I use a native DNA-binding domain compared to a truncated one for TALs?

Truncated TAL Fok1: Recommended for mammalian cells

Native TAL Fok1: Recommended for plants

Native Activators: Higher performance in non-mammalian systems

Truncated MCS: Removing endogenous activator activity

How are TALs expressed?

All TALs are expressed as Entry clones (Gateway vector-compatible, flanked by attL1 and attL2).

Fok1 TALs:
- TALs tethered with the Fok1 nuclease may be used for targeting specific genes for silencing.
- Fok1 is a Type IIs restriction endonuclease from Flavobacterium okeanokoites, consisting of an N-terminal DNA-binding domain and a C-terminal nonspecific DNA cleavage domain.
- Fok1 acts as a nuclease pair and binds to the DNA duplex at target sites designated by the binding domains resulting in subsequent cleavage.

VP16 or VP64 TALs:
- Either VP16 or VP64 may be used to increase endogenous or recombinant gene expression levels.
- VP16 is a trans-acting protein originating from the herpes simplex virus, to form a complex with host transcription factors to induce immediate early gene transcription.
- VP64 is a tetrameric form of the VP16 minimal activation domain.

MCS TALs:
- The multiple cloning site (MCS) TAL allows the user to clone any desired effector domain for targeting to any locus within the genome.

How do I transfect TALs?

Please follow standard plasmid DNA recommendations for transfection. We recommend our Invitrogen Lipofectamine 3000 and Invitrogen Lipofectamine 2000 reagents.

What is the TAL workflow?

- Design Invitrogen GeneArt TALs for target DNA, and clone into Gateway entry or destination vectors
- In vitro validation of TALs (optional)
- Transfect cells with TAL expression vectors
- TAL-mediated target cleavage
- Cleavage analysis using Invitrogen GeneArt Genomic Cleavage Detection Kit

Are TAL-meditated KO or KI strains considered GMO (genetically modified organisms)?

Yes, KO and KI strains involve editing the native genetic code by either mutating or deleting an encoded message or inserting a new piece of information at a desired site. Although this does manipulate the native genetic information, this technology, when used in a responsible manner, has very useful applications, including engineering yeasts for insulin production or engineering cells for more economically and clinically valuable products.

What is the best delivery method for TALs? Transfection, electroporation, or retroviral delivery?

mRNA and DNA are best delivered via lipid-based transfection for standard test cell lines (i.e., 293, HeLa, etc.). mRNA delivery also reduces the risk of transgene integration. We offer products including our Invitrogen Lipofectamine MessengerMAX Reagent for delivery of mRNA, and Invitrogen Lipofectamine 3000 Reagent for delivery of DNA. For stem cells, electroporation is the best option.

How fast can I get TAL constructs made so that I can do my KO or KI experiments?

Manufacturing takes place typically within 2 weeks after your order has been received.

Can TALs recognize degenerate binding sites?

By careful designing they can be engineered to be very specific. Recent publications show that 1-3 bp mismatches in target DNA sequences can be tolerated to a large extent.

Can TALs be delivered by retroviruses?

Yes. If viral-based delivery is your preferred option, we recommend adenoviral systems over lentiviral systems for TAL delivery.

How big is the TAL vector construct?

The TAL vector construct is 3.3 kb.

How specific is TAL/TALEN technology? How about off-site targeting?

A recent paper (http://www.nature.com/nbt/journal/v31/n9/abs/nbt.2675.html) by Prashant Mali in Nature Biotechnology shows that TALENs are tolerant of 1-2 mismatches, but less tolerant to a large majority of 3 bp mismatches.

What vectors are offered with the Invitrogen GeneArt PerfectMatch TALS?

We offer the N-TAL Fok1 Entry Gateway vector or the Fok1 CMV promoter–driven vector for expression.

What is the difference between Invitrogen GeneArt Precision TALs and Invitrogen GeneArt PerfectMatch TALs?

Invitrogen GeneArt PerfectMatch TALs are derived from Invitrogen GeneArt Precision TALs. PerfectMatch TALs have a new design that removes the 5′ base constraint, and therefore, can be designed to target any desired sequence in the genome. They contain 3 amino acids mutated at the N terminus of the TAL effector, which converts the 5′ binding motif to a universal binding motif able to bind to any base: A, G, C, or T. These PerfectMatch TALs can be designed with Fok1 nuclease in a Invitrogen Gateway entry vector or with CMV-driven expression for ready-to-express format for mammalian systems. PerfectMatch TALS perform as well as or better than our original Precision TALs. Currently, PerfectMatch TALs are only available with nuclease function (Fok1 Nuclease Pair), whereas Precision TALs are offered with nuclease function (Fok1 Nuclease Pair), activator function (VP16 or VP64), or custom function (MCS vector).

We compared cleavage efficiencies of PerfectMatch and Precision TALs designed for the HPRT locus using the Invitrogen GeneArt Genomic Cleavage Detection Kit, and found PerfectMatch TALs exhibit cleavage efficiencies equal to or better than the performance of Precision TALs on the same targeted region.

PerfectMatch TALs increase the flexibility of designing TAL effector targets and make it possible to keep the spacing distance between targets of TAL effector pairs at 15–16 bp to get maximal TAL effector efficiency.

What guidelines should I follow when designing a TAL sequence?

Here are our suggestions:

Invitrogen GeneArtPrecision TALs allow the construction of TAL effector functional proteins directed to either 18- or 24-base DNA target sites.

Each target site must be preceded by a 5′ T because the N terminus of the TAL effector protein contains a conserved T-binding motif. The 5′ T does not count as one of the 18 or 24 bases to be selected for targeting your specific site.

Nuclease pairs need to be designed with a spacing of 13-18 bp between the target sites on opposite strands of the DNA.

For Invitrogen GeneArt PerfectMatch TALs, there are no restrictions for the 5′ base. We developed these second-generation TALs by mutating the N-terminal domain to reduce its specificity for 5′ T. Therefore, any 5′ base (T, G, C, or A) can be used with performance comparable to that of the original Precision TALs. We recommend that you design nuclease pairs with a 15-16 bp spacing between the two TAL effectors.

The contribution of individual binding motifs within the DNA-binding domain to TAL effector binding efficiency is thought to differ, since strong and weak binding motifs exist. The A- and T-binding motifs are thought to fall within the “weak binder” category, while the C- and G-binding motifs are thought to be “strong binders”. Stretches of more than 5 weak binders should be avoided at the extreme 5′ end of the binding domain (not counting the 5′ T), or if they are not flanked by Cs. We recommended that you select a TAL effector with a DNA-binding domain composed of mixed binding motifs for best results. In the context of the living cell, DNA accessibility also determines TAL effector efficiency. It is possible that chromatin, DNA methylation, and/or proteins bound to the DNA may interfere with TAL binding. Although promoter structure varies, and specific rules regarding design are currently lacking, it is recommended that TAL transcription factors used for transcriptional activation of natural promoters be positioned upstream of the TATA box, or in some cases downstream of the transcriptional start site. Selecting a target site directly over the TATA box or other known transcription factor binding site is not recommended. Be sure that the natural ATG is present, and that no premature ATG which may interfere with the natural translational start is transcribed.

What available functionality (effector domains) do you offer for TALs?

Please view the available effector domains (https://www.thermofisher.com/us/en/home/life-science/cloning/gene-synthesis/geneart-precision-tals.html#table1).

What is the turnaround time for receiving custom TALs?

We will ship you a clone with a verified, optimized sequence approximately 2 weeks after confirming your order.

What are the benefits of using TAL/TALEN-based genome editing compared to your CRISPR system?

Invitrogen GeneArt Precision TALs, in addition to gene deletion, down-regulation and integration, can also be used for gene activation. Additionally, the system is based on a protein-DNA system, in contrast to CRISPR, which is based on a RNA-DNA system. TALs can be used to target any gene in any cell, including mammalian, bacterial, yeast, plants, insect, stem cells and zebrafish. Lastly, off-target effects are low when using the TAL system. Please refer to the following paper (http://www.sciencedirect.com/science/article/pii/S016816561500200X) where the authors compared TALs and CRISPR technology.

Why should I use TAL/TALEN technology?

- One-to-one relationship between two critical amino acids in each repeat and each DNA base in the target sequence

- Simple code for creating engineered TALs

- More predictable than zinc fingers

- Modular assembly of domains allows engineering of sequence-specific DNA-binding proteins

- Can be coded to deliver functionality to a specific locus for: nucleases, activators, repressors, chromatin modifiers

Can you elaborate on your suggestion to use CRISPR as a screening tool before going to TALs?

Since cleavage efficiency at a particular locus depends on the accessibility of the locus, chromatin state, and sequence, it is advisable to test multiple different loci/regions within a gene of interest. With CRISPR-Cas9-mediated genome editing, for each target of interest the user needs only to change the 19-20 bp target-specific oligo. After the cell lines have been screened and the sequence/locus with the highest cleavage efficiency has been identified, the biologically relevant mutations can be precisely created with high-specificity Invitrogen GeneArt TALs (https://www.thermofisher.com/us/en/home/life-science/genome-editing/geneart-tals.html).

What is the advantage of generating gene knockouts by TAL or CRISPR compared to vector-based stably expressed shRNA?

TAL and CRISPR directly edit the genome by a combined cleavage and repair mechanism to impart permanent genomic change (deletion or frameshift mutation), and the resulting gene knockouts are very efficient. RNAi technology, on the other hand, is an indirect method in either down-regulating or shutting down a gene completely through direct interaction with RNA (coding or noncoding). Even in the case for stably expressed miRNA or shRNA systems, it may be difficult to effect complete penetrance (i.e., shRNA:mRNA ratio) since knock-down levels are dependent on the activity of the promoter (related to integration location).